The Site-specific Conjugation Strategy of HER2-targeted Antibody-drug Conjugates and its Application in Tumor Treatment
DOI:
https://doi.org/10.54097/2134ew21Keywords:
HER2-targeted Antibody-drug Conjugate, Site-specific Conjugation Strategy, Tumor Therapy, her2-positive Tumor, Drug Resistance MechanismAbstract
This paper focuses on the site-specific conjugation strategies of HER2-targeted antibody-drug conjugates (ADCs) and their applications in tumor therapy. First, it elaborates on the biological characteristics of HER2-positive tumors, the current treatment status, the rise of antibody-drug conjugates, and the necessity of site-specific conjugation strategies. Then, it introduces various site-specific conjugation strategies for HER2-targeted ADCs, such as engineered cysteines and non-natural amino acid insertion, conducts technical comparisons and optimizations, and lists representative drugs. Next, it explores the applications of site-specific conjugated ADCs in tumor therapy, including clinical efficacy, mechanisms to overcome drug resistance, and safety optimization. Finally, it analyzes the challenges in technology and clinical practice and presents prospects for future research directions. This study contributes to promoting the further development of HER2-targeted ADCs in tumor therapy.
Downloads
References
[1] She, D. Y., Huang, J. H., Liu, D. C., et al. (2015). Preparation and biological activity study of Her2 antibody-MMAE conjugate. China Biotechnology,35(02),66-71.
[2] Liang, X. J., Gong, L. Y., Zhou, F., et al. (2019). Pharmacological activity of anti-human epidermal growth factor receptor 2 antibody-drug conjugate prepared by site-specific conjugation with unnatural amino acid. Journal of Peking University (Health Sciences),51(05),797-804.
[3] Badescu, G., Bryant, P., Bird, M., et al. (2014). Bridging Disulfides for Stable and Defined Antibody Drug Conjugates. Bioconjugate Chemistry, 25(6), 1124–1136.
[4] van der Lee, M. M. C., Groothuis, P. G., Ubink, R., et al. (2015). The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers. Molecular Cancer Therapeutics, 14(3), 692–703.
[5] Axup, J. Y., Bajjuri, K. M., Ritland, M, et al. (2012). Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proceedings of the National Academy of Sciences of the United States of America, 109(40), 16101–16106.
[6] Drago, J. Z., Modi, S., Chandarlapaty, S., et al. (2021). Unlocking the potential of antibody–drug conjugates for cancer therapy. Nature Reviews Clinical Oncology, 18(6), 327–344.
[7] Strop, P. , Liu, S. H. , Dorywalska, M. , Delaria, K. , et al. (2013). Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chemistry & biology,20(2), 161-167.
[8] Barok, M., Le Joncour, V., Martins, A., et al. (2019). Preclinical activity of HER2-targeting antibody-drug conjugate DHES0815A in HER2-positive and -low breast cancer models. Cancer Research, 79(4_Supplement), P6-17-03.
[9] Popp, M. W., Dougan, S. K., Chuang, T.-Y., et al. (2011). Sortase-catalyzed transformations that improve the properties of cytokines. Proceedings of the National Academy of Sciences of the United States of America, 108(8), 3169–3174.
[10] van Geel, R., Wijdeven, M. A., Heesbeen, R., et al. (2015). Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody–Drug Conjugates. Bioconjugate Chemistry, 26(11), 2233–2242.
[11] Li, T., Tong, X. , Yang, Q., Giddens, J. P., et al. (2016). Glycosynthase mutants of endoglycosidase s2 show potent transglycosylation activity and remarkably relaxed substrate specificity for antibody glycosylation remodeling. Journal of Biological Chemistry,291(32), 16508.
[12] Andreev, J., Thambi, N., Perez Bay, A. E., et al. (2017). Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs. Molecular Cancer Therapeutics, 16(4), 681–693.
[13] Li, Q., Cheng, Y., Tong, Z., et al. (2024). HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial. Nature Communications, 15(1).
[14] Junutula, J. R., Flagella, K. M., Graham, R. A., et al. (2010). Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer. Clinical Cancer Research, 16(19), 4769–4778.
[15] Shitara, K., Bang, Y.-J., Iwasa, S., et al. (2020). Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. New England Journal of Medicine, 382(25), 2419–2430.
[16] Modi, S., Park, H., Murthy, R. K., et al. (2020). Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study. Journal of Clinical Oncology, 38(17), 1887–1896.
[17] Strop, P., Delaria, K., Foletti, D., et al. (2015). Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading. Nature Biotechnology, 33(7), 694–696.
[18] Okajima, D., Yamaguchi, J., Kitamura, M., et al. (2019). Abstract C026: DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, demonstrates potent antitumor activity in preclinical models. Molecular Cancer Therapeutics, 18(12_Supplement), C026–C026.
[19] Dokter, W., Ubink, R., van der Lee, M., et al. (2014). Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform. Molecular Cancer Therapeutics, 13(11), 2618–2629.
[20] Gramer, M. J., van den Bremer, E. T., van Kampen, M. D., et al.(2013). Production of stable bispecific IgG1 by controlled Fab-arm exchange. MAbs, 5(6), 962–973.
[21] Shang, C., Yang, L., Zhang, J., et al. (2022). Abstract 4256: YH012, a novel bispecific anti-HER2 and TROP2 antibody-drug conjugate, exhibits potent antitumor efficacy. Cancer Research, 82(12_Supplement), 4256–4256.
[22] Modi, S., Jacot, W., Yamashita, T., et al. (2022). Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. New England Journal of Medicine, 387(1).
[23] Taylor, M. L., Dada, H. I., Florian, H., et al.(2021). Identification of pathogenic CDK12 alterations in cell-free DNA (cfDNA) from patients with breast cancer. Journal of Clinical Oncology, 39(15_Supplement), 1028–1028.
[24] Li, G., Guo, J., Shen, B.-Q., et al. (2018). Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells. Molecular Cancer Therapeutics, 17(7), 1441–1453.
[25] Cortés, J., Kim, S.-B., Chung, W.-P., et al. (2022). Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. New England Journal of Medicine, 386(12), 1143–1154.
[26] Beck, A., Goetsch, L., Dumontet, C., et al.(2017). Strategies and Challenges for the next Generation of Antibody–drug Conjugates. Nature Reviews Drug Discovery, 16(5), 315–337.
[27] Modi, S., Saura, C., Yamashita, T., et al. (2020). Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. New England Journal of Medicine, 382(7), 610–621.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
